Marketing Group I Presentation By Anawat Pinisakul Myat Htay Kyi Salaya Phunsiri

Presentation Outline b b Introduction HIV/AIDS patients b b Marketing Aspects Cost of drug GDP VS Drug Cost HIV in Thailand Drug production approximation b b Conclusions and Recommendations

Estimated Number of People Estimated Number of Infected People in the World North AmericaOceania Latin America Sub-Saharan Africa Caribbean Eastern Europe SE Mediterranean Northeast Asia Southeast AsiaWestern Europe Geographic Region

Cost of Drug b Protease inhibitors cost $6,000-$8,000 per year b Bulk-purchase In Uruguay, two-third of the quoted pricesIn Uruguay, two-third of the quoted prices

Total cost implication of providing anti-retroviral therapy Estimated Cost ($billion) North America Western Europe Oceania Latin America Sub-Saharan Africa Caribbean Eastern Europe SE Mediterranean Northeast Asia Southeast Asia

GDP VS Drug Cost

Distribution of reported AIDS cases by year of diagnosis in Thailand,

Percentage of reported AIDS cases by risk factor, Thailand, September 1984 – 31 May 2000

Distribution of AIDS cases by occupation and sex September April 2000

Average wage by industry in Thailand b Cost of ritonavir = US$8,308 per year

Drug production approximation b Ritonavir b Dosage = 600 mg per person (twice a day) = 1,200 mg/day per person = 438 g/yr person b Estimated and reported case of AIDS = 470,000 and 144,250, respectively b Reported case is only 30% of estimated

Drug Production Approximation b 1.3 million of infected HIV estimated by the year 2000 b 390,000 reported HIV infected b 10% die because of AIDS b 351,000 Survived HIV infected to be treated b Assume, 50% of surviving HIV infected can consume drug (175,500 persons)

Drug production approximation b 10 types of drugs b 10% of patients use Ritonavir b Production for 17,550 HIV infected persons b Ritonavir production = 7,690 kg/yr

Conclusions and Recommendations b Consideration Number of HIV patientsNumber of HIV patients Income of populationIncome of population Type of drugType of drug Government and private sectorGovernment and private sector b ARV therapy does appear affordable and cost- effective in high-income countries

Conclusions and Recommendations b Thailand is the second largest HIV infected population b Low GDP b Thais cannot afford antiretroviral therapy